An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A medical team reported using an unusual combination therapy to help a child who had both type 1 diabetes (where the body doesn't make insulin) and features of type 2 diabetes (like insulin resistance). In one patient already on an insulin pump, doctors added an off-label fixed mix of long-acting insulin degludec and liraglutide (a drug that affects appetite and blood sugar). This was written up as a single case in a medical journal, not a large trial. Liraglutide is a medicine originally developed for type 2 diabetes and also used for weight management. It copies a natural hormone from the gut that makes you feel full and helps control blood sugar by signaling the body to release insulin and slow digestion. Insulin degludec is a very long-acting insulin that keeps baseline blood sugar down. The fixed-ratio product combines both in one injection; it’s approved in adults for some types of diabetes, but not routinely in children or for mixing with insulin pumps. What the write-up actually shows is a single-patient experience where clinicians tried this combined injection in a pediatric patient with “double diabetes” who was struggling despite pump therapy. Because it’s a case report, it can describe how that one child did after the change — improvements in blood sugar patterns, weight, or insulin needs might be noted — but it doesn’t prove the approach works broadly. There’s no control group, and a single case can’t tell us about typical benefit, how often it helps, or rare side effects. Why this matters is practical: managing kids who have autoimmune diabetes plus weight-related insulin resistance is hard. If a medicine that reduces appetite and insulin resistance can be safely added, it might lower the amount of insulin needed and improve blood sugar control. Parents, pediatric endocrinologists, and people watching diabetes care trends would care because it points to a possible option where standard treatments aren’t enough. It also raises questions about how to combine newer drugs with existing insulin technologies. There are important cautions. This use was off-label for a child and not a formal clinical trial. Liraglutide can cause nausea, and in rare cases has been linked to pancreatitis (inflammation of the pancreas) and other concerns; long-acting insulins carry the usual risk of low blood sugar. We don’t know long-term safety or whether the result would repeat in other children. Anyone curious about this approach should discuss it with their specialist; doctors should weigh risks, monitor closely, and prefer enrolling patients in controlled studies when possible. Bottom line: A single case suggests combining a long-acting insulin with liraglutide might help a child with both types of diabetes, but it’s early and not proof — more research is needed before this becomes a standard option.
Source: Cureus